Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of ANeuroTech.

    Client Virtual Booth

    ANEUROTECH

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    ANeuroTech
    Belgium Flag
    Country
    Country
    Belgium
    Address
    Address
    Alkerstraat 30A, 3570 Alken
    Telephone
    Telephone
    + 32 11 94 91 15
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.aneurotech.com/
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    ANeuroTech Receives IND Approval from the FDA for Pivotal Phase IIIB Trial of Adjunctive Anti-Depression Drug, ANT-01

    Details:

    ANT01 (pipamperone dihydrochlorideshows) a unique combined high BLOCKING affinity toward the human serotonin 2A and dopamine 4 receptor, which being invetigated for for Major Depressive Disorder.


    Lead Product(s): Pipamperone

    Therapeutic Area: Psychiatry/Psychology Product Name: ANT-01

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable June 05, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Aneurotech Receives Positive Feedback From the FDA for Its Pivotal Phase IIIb Development Programme for ANT-01 as an Adjunctive Anti-depression Drug for...

    Details:

    The data for ANT-01 (pipamperone dihydrochloride) showed an improvement in the ability to feel pleasure and in cognitive function, which has not been demonstrated by any other antidepressant molecule.


    Lead Product(s): Pipamperone,Undisclosed

    Therapeutic Area: Psychiatry/Psychology Product Name: ANT-01

    Highest Development Status: PreclinicalProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Johnson & Johnson

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 05, 2022

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    bora-pharmaceuticals-2024-07-01

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search